Richard Conway RichardPAConway
1 year 6 months ago
Dr Rhee @RennieRhee mimics of medium/large vessel vasculitis. Increase in cross-sectional imaging use has increased the number of these we get referred. Segmental arterial mediolysis also pops up a fair bit. @RheumNow #RNL2025 https://t.co/yozRGE9Ncl
Adela Castro AdelaCastro222
1 year 6 months ago
ICYMI: Treatment of sclerosing skin disease:
-Progression: inflammation➡️sclerosis➡️ atrophy
-Existing therapies target inflammation not sclerosis-poorly developed ttx for sclerosis
-First aspect is determining disease state, depth of involvement, extracutaneous manifestations… https://t.co/lYQRW2yDRG https://t.co/DQZjYKS2Ks
Dr Gurdeep S Dulay gurdeep_dulay
1 year 6 months ago
🆕 slide from @Official_ASAS
HLA-B27 strongly associated with Anterior #Uveitis in #SpA
#AAU #AxSpA #B27 https://t.co/lq19vIys9x
Eric Dein ericdeinmd
1 year 6 months ago
@RichardPAConway on PMR
#RNL2025 @RheumNow
PMR mimics: look for mimics in unusual/refractory cases
- Suspect the mimics to avoid undertreatment or over-treatment
Conway: PMR is NOT easy. Easy to misdiagnosis, easy to mistreat. "One of our most challenging cases" https://t.co/WqPWwCuutF
Dr. John Cush RheumNow
1 year 6 months ago
Eric Dein @ericdeinmd
🏈Kick-off of @RheumNow w Jeff Curtis #RNL2025 🏈 AI in RA? Can help with Rheum Boards Questions, though AI is not confident in answers May not be better than paper charts for triage Other roles: pt chatbot, AI scribe, research populations, generate DDx,… https://t.co/3vJ2gON6tR https://t.co/3ArtaRkhJp
Dr. John Cush RheumNow
1 year 6 months ago
TheDaoIndex @KDAO2011
Potential uses of #AI for #RA -office workflow (scribe, triage) -research (match eligible pts for trials) -help with diagnosis (and likelihood of risk) -consume guidelines for disease mgmt @RADoctor #RNL2025 https://t.co/k2nOytpKBH https://t.co/7Y2OvBv9pP
The development of AI and other technologies brings new possibilities for optimizing diagnosis, management and has potential for improving outcomes in RA. At RheumNow Live 2025, Dr. Jeff Curtis, University of Alabama at Birmingham, presented a talk on, "AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect".
Dr. John Cush RheumNow
1 year 6 months ago
QD Clinic - Recurrent Acute Oligoarthritis Recurrent Acute Oligoarthritis in a 40 yr. old man https://t.co/5D5qE05u1w https://t.co/tunU955MkH
A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.
Dr. John Cush RheumNow
1 year 6 months ago
Cannabis Hospitalizations and Mortality Risk
A Canadian population, retrospective cohort study shows individuals needing hospital-based (emergency department or hospitalization) care for a cannabis use disorder (CUD) were at increased risk of death.
https://t.co/MQtR3etpEH https://t.co/ZB4byi81on
The always compelling Dr. Alexis Ogdie explored whether aggressive treatment of psoriasis can prevent psoriatic arthritis in an excellent Saturday morning session at RheumNow Live 2025.
Dr. John Cush RheumNow
1 year 6 months ago
SLE subphenotypes predisposed by distinct genetic risk loci. Multicenter 10 yr genotyping study on 1462 SLE pts (56% w/ lupus nephritis & 43% not LN) found significantly higher polygenic risk scores (PRS); significant LN variants included HLA, TNFAIP3, BLK, & STAT4.… https://t.co/5igpgtdE1U https://t.co/5KOXRThzlk
Dr. John Cush RheumNow
1 year 6 months ago
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/vwgfa5z6BE https://t.co/N1yUcrcR2o
Richard Conway RichardPAConway
1 year 6 months ago
Dr Cather treatment options in HS. The last 2 obviously in rheumatology's wheelhouse @RheumNow #RNL2025 https://t.co/vGfvQH05lv
Eric Dein ericdeinmd
1 year 6 months ago
New for HS
- Bimekizumab is 3rd FDA approved therapy based on BE HEARD 1&2
- Other approved ADA (2015, PIONEER 1&2), SEC (2023, SUNRISE/SUNSHINE)
Clinical trials:
IL23 failed, ILalpha failed
Brodulamab (IL17a) clinically meaningful response
TNF trials
@RheumNow #ACR2025 https://t.co/BfzwNQ1wUB
